Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Panitumumab for Prevention of Myopic Axial Elongation
DRKS00027302Phase 2Active, not recruiting
- Sponsor
- Ufa Eye Research Institute
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of panitumumab in Pathologic Myopia (PM), degenerative myopia and myopic maculopathy (MM) (2 arms), sponsored by Ufa Eye Research Institute. Started Dec 2021; status: active, not recruiting.
02
Drugs
panitumumab
03
Conditions
Pathologic Myopia (PM)degenerative myopiamyopic maculopathy (MM)
Beyond the preview
Go deeper on DRKS00027302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00027302.